NCT03101267View on ClinicalTrials.gov

A Dose-finding Study of ASP4070

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 13, 2017

Primary Completion Date

January 26, 2018

Study Completion Date

October 27, 2018

Conditions
Rhinitis, Allergic, Seasonal
Interventions
DRUG

ASP4070

Intradermal vaccination at 2-week intervals

DRUG

Placebo

Intradermal vaccination at 2-week intervals

Trial Locations (1)

Unknown

Site JP00001, Shinjuku

Sponsors
All Listed Sponsors
collaborator

Immunomic Therapeutics, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY